CL2008001634A1 - Anticuerpo de la region regulatoria negativa anti-notch1 aislado; polinucleotido que lo codifica; vector y celula huesped; metodo de produccion; composicion que lo comprende; y su uso para preparar un medicamento para tratar un trastorno asociado con un aumento en la señalizacion o expresion de notch1 en un individuo. - Google Patents
Anticuerpo de la region regulatoria negativa anti-notch1 aislado; polinucleotido que lo codifica; vector y celula huesped; metodo de produccion; composicion que lo comprende; y su uso para preparar un medicamento para tratar un trastorno asociado con un aumento en la señalizacion o expresion de notch1 en un individuo.Info
- Publication number
- CL2008001634A1 CL2008001634A1 CL2008001634A CL2008001634A CL2008001634A1 CL 2008001634 A1 CL2008001634 A1 CL 2008001634A1 CL 2008001634 A CL2008001634 A CL 2008001634A CL 2008001634 A CL2008001634 A CL 2008001634A CL 2008001634 A1 CL2008001634 A1 CL 2008001634A1
- Authority
- CL
- Chile
- Prior art keywords
- notch1
- antibody
- vector
- hvr
- polynucleotide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
Abstract
UN ANTICUERPO DE LA REGIÓN REGULATORIA NEGATIVA (NRR) ANTI-NOTCHL AISLADO, SE UNE A UN NOTCH1 NRR CON UNA KD DE 1 X 10-7 O MAYOR, DONDE DICHO ANTICUERPO, CUANDO SE UNE A DICHO NOTCHL NRR, DISMINUYE LA SEÑALIZACIÓN DE NOTCH1, Y DONDE EL ANTICUERPO COMPRENDE HVR•L1, HVR•L2, HVR•L3, HVR•HL. HVR•H2 Y HVR•H3, DONDE CADA UNO, EN ORDEN, COMPRENDE: (I) SEA ID NO: 7, 8, 9, 1, 2, 6; (II)SEO ID NO: 7, 8, LA, 1, 3, 6; (III) SEA ID NO: 7, 8,11,1,4,6; O (IV) SEA ID NO: 7, 8, 12, 1, 5, 6. UN POLINUCLEÓTIDO QUE LO CODIFICA. UN VECTOR QUE COMPRENDE DICHO POLINUCLEÓTIDO. UNA CÉLULA HUÉSPED QUE COMPRENDE DICHO VECTOR. UN MÉTODO PARA PREPARAR UN ANTICUERPO ANTI-NOTCH1 NRR, DONDE DICHO MÉTODO COMPRENDE (A) EXPRESAR DICHO VECTOR EN UNA CÉLULA HUÉSPED ADECUADA Y (B) RECUPERAR EL ANTICUERPO. UNA COMPOSICIÓN QUE COMPRENDE UN ANTICUERPO ANTI-NOTCH1 NRR. USO DE UNA CANTIDAD EFECTIVA DE UN ANTICUERPO ANTI-NOTCH1 NRR, PARA PREPARAR UN MEDICAMENTO ÚTIL PARA TRATAR TRASTORNOS ASOCIADOS CON AUMENTO DE LA SEÑALIZACIÓN O EXPRESIÓN DE NOTCH1 O CON UNA MUTACIÓN EN UNA SECUENCIA DE AMINOÁCIDOS DE NOTCH1 EN UN INDIVIDUO, PARA TRATAR CÁNCER, UN TUMOR Y/O UN TRASTORNO PROLIFERATIVO CELULAR EN UN INDIVIDUO, ENTRE OTROS.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93307207P | 2007-06-04 | 2007-06-04 | |
US99464607P | 2007-09-20 | 2007-09-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2008001634A1 true CL2008001634A1 (es) | 2009-05-22 |
Family
ID=39735560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2008001634A CL2008001634A1 (es) | 2007-06-04 | 2008-06-04 | Anticuerpo de la region regulatoria negativa anti-notch1 aislado; polinucleotido que lo codifica; vector y celula huesped; metodo de produccion; composicion que lo comprende; y su uso para preparar un medicamento para tratar un trastorno asociado con un aumento en la señalizacion o expresion de notch1 en un individuo. |
Country Status (29)
Country | Link |
---|---|
US (5) | US8846871B2 (es) |
EP (1) | EP2152748B1 (es) |
JP (4) | JP5623272B2 (es) |
KR (2) | KR20160043128A (es) |
CN (1) | CN101796074B (es) |
AR (1) | AR066846A1 (es) |
BR (1) | BRPI0811382A2 (es) |
CA (1) | CA2687866C (es) |
CL (1) | CL2008001634A1 (es) |
CO (1) | CO6150200A2 (es) |
CR (2) | CR11139A (es) |
CY (1) | CY1114690T1 (es) |
DK (1) | DK2152748T3 (es) |
EC (1) | ECSP099785A (es) |
ES (1) | ES2432798T3 (es) |
HK (1) | HK1141040A1 (es) |
HR (1) | HRP20131107T1 (es) |
IL (3) | IL202183A0 (es) |
MA (1) | MA31502B1 (es) |
MX (1) | MX2009013199A (es) |
NZ (1) | NZ581303A (es) |
PE (1) | PE20090321A1 (es) |
PH (1) | PH12015500550A1 (es) |
PL (1) | PL2152748T3 (es) |
PT (1) | PT2152748E (es) |
RU (1) | RU2476443C2 (es) |
SI (1) | SI2152748T1 (es) |
TW (1) | TWI458737B (es) |
WO (1) | WO2008150525A1 (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6984522B2 (en) * | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
PL2032166T3 (pl) | 2006-06-13 | 2013-09-30 | Oncomed Pharm Inc | Kompozycje i sposoby diagnozowania i leczenia nowotworów |
CA2666672A1 (en) | 2006-10-19 | 2008-05-02 | Genentech, Inc. | Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases |
EP2081962B1 (en) | 2006-10-19 | 2018-10-03 | Genentech, Inc. | Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease |
JP5386364B2 (ja) | 2006-12-18 | 2014-01-15 | ジェネンテック, インコーポレイテッド | 抗Notch3アンタゴニスト抗体とNotch3関連疾患の予防及び治療におけるその使用 |
AU2008209482B2 (en) | 2007-01-24 | 2014-05-01 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
PE20090321A1 (es) | 2007-06-04 | 2009-04-20 | Genentech Inc | Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica |
ES2531541T3 (es) | 2008-07-08 | 2015-03-17 | Oncomed Pharmaceuticals, Inc. | Agentes de unión del receptor Notch1 y procedimientos de uso de los mismos |
US9132189B2 (en) | 2008-07-08 | 2015-09-15 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
EP2334331B1 (en) | 2008-10-01 | 2015-04-29 | F. Hoffmann-La Roche AG | Anti-notch2 antibodies and methods of use |
CN102686610A (zh) * | 2009-06-18 | 2012-09-19 | 辉瑞公司 | 抗刻缺蛋白-1抗体 |
WO2011009064A1 (en) * | 2009-07-17 | 2011-01-20 | The J. David Gladstone Institutes | Methods of controlling cell proliferation |
PE20120998A1 (es) | 2009-09-30 | 2012-08-14 | Genentech Inc | Metodos para el tratamiento del cancer usando antagonistas de notch |
US8945569B2 (en) | 2009-11-19 | 2015-02-03 | Oncomed Pharmaceuticals, Inc. | Jagged-binding agents and uses thereof |
AU2011205316B2 (en) * | 2010-01-13 | 2015-05-28 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
MX341687B (es) | 2010-02-10 | 2016-08-30 | Immunogen Inc | "anticuerpos cd20 y su utilización". |
BR112013015122A2 (pt) * | 2010-12-15 | 2017-05-30 | Wyeth Llc | anticorpos anti-notch1 |
WO2012080891A1 (en) * | 2010-12-15 | 2012-06-21 | Rinat Neuroscience Corp. | Anti-notch-1 antibodies |
US20130089562A1 (en) | 2011-10-05 | 2013-04-11 | Genenthech, Inc. | Methods of treating liver conditions using notch2 antagonists |
EP2606884A1 (en) | 2011-12-21 | 2013-06-26 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Inhibitors of notch signaling pathway and use thereof in treatment of cancers |
JP6352264B2 (ja) | 2012-08-13 | 2018-07-04 | ジェネンテック, インコーポレイテッド | 抗jagged抗体および使用方法 |
US9550829B2 (en) | 2013-03-15 | 2017-01-24 | Genentech, Inc. | Compositions and methods for diagnosis and treatment of hepatic cancers |
WO2014172653A2 (en) * | 2013-04-19 | 2014-10-23 | Aveo Pharmaceuticals, Inc. | Anti-notch1 antibodies |
TWI631135B (zh) | 2014-02-12 | 2018-08-01 | 建南德克公司 | 抗jagged1抗體及使用方法 |
WO2015134627A1 (en) * | 2014-03-07 | 2015-09-11 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancer with notch1 antibodies |
AU2015264120A1 (en) * | 2014-05-22 | 2016-11-24 | Board Of Regents Of The University Of Texas System | LILRB2 and notch-mediated expansion of hematopoietic precursor cells |
CA2952315A1 (en) | 2014-07-11 | 2016-01-14 | Genentech, Inc. | Notch pathway inhibition |
EP3212773B1 (en) | 2014-10-29 | 2021-09-15 | Massachusetts Eye and Ear Infirmary | Efficient delivery of therapeutic molecules to cells of the inner ear |
CA3035081A1 (en) | 2016-09-02 | 2018-03-08 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating b cell disorders |
US20180230218A1 (en) | 2017-01-04 | 2018-08-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
WO2018222880A1 (en) * | 2017-05-31 | 2018-12-06 | Trustees Of Boston University | Mechano-activated control of gene expression |
EP3743057A4 (en) | 2018-01-26 | 2021-11-17 | Massachusetts Eye & Ear Infirmary | TREATMENT OF HEARING LOSS |
WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
EP3827021A4 (en) * | 2018-07-23 | 2022-08-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | ANTIBODIES TARGETING A COMPLEX INCLUDING UNCLASSICAL HLA-I AND NEOANTIGEN AND METHODS OF USE THEREOF |
US20240043934A1 (en) * | 2020-08-22 | 2024-02-08 | The Broad Institute, Inc. | Pancreatic ductal adenocarcinoma signatures and uses thereof |
TW202308702A (zh) | 2021-04-30 | 2023-03-01 | 美商西建公司 | 使用抗BCMA抗體藥物結合物(ADC)組合γ分泌酶抑制劑(GSI)之組合療法 |
AU2022358772A1 (en) * | 2021-10-10 | 2024-05-02 | Elixiron Immunotherapeutics (hong Kong) Limited | Method of treating diseases with anti-pd-l1/il-10 fusion proteins |
Family Cites Families (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3720760A (en) | 1968-09-06 | 1973-03-13 | Pharmacia Ab | Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples |
GB1319315A (en) | 1969-06-19 | 1973-06-06 | Citizen Watch Co Ltd | Calendar timepiece |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3940475A (en) | 1970-06-11 | 1976-02-24 | Biological Developments, Inc. | Radioimmune method of assaying quantitatively for a hapten |
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5079233A (en) | 1987-01-30 | 1992-01-07 | American Cyanamid Company | N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
IL101728A (en) | 1991-05-03 | 2007-08-19 | Univ Yale | Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them |
IE20030749A1 (en) * | 1991-05-03 | 2003-11-12 | Indiana University Foundation | Human notch and delta binding domains in torporythmic proteins, and methods based thereon |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
US5786158A (en) * | 1992-04-30 | 1998-07-28 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
US20050112121A1 (en) * | 1992-04-30 | 2005-05-26 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
DK1167384T3 (da) | 1992-10-28 | 2007-04-10 | Genentech Inc | Vaskular endotheliel cellevækstfaktor antagonister |
JP3095175B2 (ja) | 1992-11-13 | 2000-10-03 | アイデック ファーマシューティカルズ コーポレイション | B細胞リンパ腫の治療のためのヒトbリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用 |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
US5639635A (en) | 1994-11-03 | 1997-06-17 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
US5780300A (en) * | 1995-09-29 | 1998-07-14 | Yale University | Manipulation of non-terminally differentiated cells using the notch pathway |
US20050158859A1 (en) * | 1995-09-29 | 2005-07-21 | Yale University | Manipulation of non-terminally differentiated cells using the Notch pathway |
WO1997038123A1 (en) | 1996-04-05 | 1997-10-16 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells |
FR2751986B1 (fr) * | 1996-08-01 | 1998-12-31 | Inst Nat Sante Rech Med | Gene implique dans le cadasil, methode de diagnostic et application therapeutique |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
DE69829891T2 (de) | 1997-04-07 | 2005-10-06 | Genentech, Inc., South San Francisco | Anti-VEGF Antikörper |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
DK0971959T3 (da) | 1997-04-07 | 2006-05-15 | Genentech Inc | Humaniserede antistoffer og fremgangsmåder til dannelse af humaniserede antistoffer |
US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
US6436650B1 (en) * | 1997-07-23 | 2002-08-20 | Yale University | Activated forms of notch and methods based thereon |
US6692919B1 (en) * | 1997-07-23 | 2004-02-17 | Yale University | Activated forms of notch and methods based thereon |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
IL138608A0 (en) | 1998-04-02 | 2001-10-31 | Genentech Inc | Antibody variants and fragments thereof |
AU768269B2 (en) * | 1998-10-02 | 2003-12-04 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Apoptosis inducing agents and methods |
KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
US6149202A (en) * | 1999-04-12 | 2000-11-21 | Bertek Systcms, Inc. | Page marker carrier assembly and production thereof |
US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
US8084258B2 (en) * | 1999-07-12 | 2011-12-27 | University Of Basel | Manipulation of tissue of organ type using the notch pathway |
US20020081597A1 (en) | 2000-03-31 | 2002-06-27 | Genentech, Inc. | Compositions and methods for detecting and quantifying gene expression |
DK1318830T3 (da) * | 2000-09-22 | 2013-01-28 | Genentech Inc | Konstitutivt aktiv form af Notch1-receptor eller et anti-Notch1-receptor til behandling af prostatacancer |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
WO2003042246A2 (en) | 2001-11-14 | 2003-05-22 | Lorantis Limited | Inhibitors of the notch signalling pathway for use in the treatment of cancer |
JP4432031B2 (ja) * | 2002-03-22 | 2010-03-17 | ズィナイス オペレーションズ ピーティーワイ.エルティーディー. | インターロイキン13受容体α1(IL−13Rα1)に対するモノクローナル抗体 |
AU2003255735A1 (en) * | 2002-08-03 | 2004-02-23 | Lorantis Limited | Conjugate of notch signalling pathway modulators and their use in medical treatment |
EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
KR20070055625A (ko) | 2002-12-16 | 2007-05-30 | 제넨테크, 인크. | 이뮤노글로불린 변이체 및 이들의 용도 |
AU2003288675B2 (en) | 2002-12-23 | 2010-07-22 | Medimmune Limited | Antibodies against PD-1 and uses therefor |
US20060194315A1 (en) * | 2003-03-31 | 2006-08-31 | Condie Brian G | Compositions and methods for the control, differentiaton and/or manipulation of pluripotent cells through a gamma-secretase signaling pathway |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
JP2007512348A (ja) | 2003-11-26 | 2007-05-17 | ヘルス リサーチ インコーポレイテッド | 形質細胞の治療のためのノッチ経路干渉剤の使用 |
CA2810292C (en) * | 2004-05-14 | 2015-09-29 | Euroscreen S.A. | Ligand for g-protein coupled receptor fprl2 and uses thereof |
US20070077245A1 (en) | 2004-08-04 | 2007-04-05 | The Brigham And Women's Hospital, Inc. | NOTCH mutations leading to increased receptor signaling |
WO2006053063A2 (en) * | 2004-11-05 | 2006-05-18 | The Regents Of The University Of California | Notch-1 assay to detect neurodegenerative diseases |
WO2006068822A1 (en) * | 2004-12-20 | 2006-06-29 | Genentech, Inc. | Notch receptor agonists and uses |
JP5328156B2 (ja) * | 2005-02-03 | 2013-10-30 | マクロジェニックス ウエスト, インコーポレイテッド | オンコスタチンmレセプターに対する抗体 |
US20090305310A1 (en) * | 2005-11-22 | 2009-12-10 | University Of Vermont And State Agricultural College | Methods for Determining Notch Signaling and Uses Thereof |
WO2007070671A2 (en) * | 2005-12-16 | 2007-06-21 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with dll4 antagonists |
US20080241150A1 (en) * | 2006-05-15 | 2008-10-02 | The Brigham And Women's Hospital, Inc. | Functional negative regulatory domain sequences from human NOTCH1 and 2 and isolated LNR domains from human NOTCH1 |
CA2666672A1 (en) * | 2006-10-19 | 2008-05-02 | Genentech, Inc. | Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases |
JP5386364B2 (ja) * | 2006-12-18 | 2014-01-15 | ジェネンテック, インコーポレイテッド | 抗Notch3アンタゴニスト抗体とNotch3関連疾患の予防及び治療におけるその使用 |
PE20090321A1 (es) | 2007-06-04 | 2009-04-20 | Genentech Inc | Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica |
PE20120998A1 (es) * | 2009-09-30 | 2012-08-14 | Genentech Inc | Metodos para el tratamiento del cancer usando antagonistas de notch |
WO2012080891A1 (en) | 2010-12-15 | 2012-06-21 | Rinat Neuroscience Corp. | Anti-notch-1 antibodies |
BR112013015122A2 (pt) | 2010-12-15 | 2017-05-30 | Wyeth Llc | anticorpos anti-notch1 |
-
2008
- 2008-06-02 PE PE2008000929A patent/PE20090321A1/es not_active Application Discontinuation
- 2008-06-03 WO PCT/US2008/007000 patent/WO2008150525A1/en active Application Filing
- 2008-06-03 DK DK08768087.2T patent/DK2152748T3/da active
- 2008-06-03 PT PT87680872T patent/PT2152748E/pt unknown
- 2008-06-03 CN CN200880101359.0A patent/CN101796074B/zh not_active Expired - Fee Related
- 2008-06-03 RU RU2009149462/10A patent/RU2476443C2/ru not_active IP Right Cessation
- 2008-06-03 EP EP08768087.2A patent/EP2152748B1/en not_active Revoked
- 2008-06-03 KR KR1020167008809A patent/KR20160043128A/ko active IP Right Grant
- 2008-06-03 JP JP2010511175A patent/JP5623272B2/ja not_active Expired - Fee Related
- 2008-06-03 NZ NZ581303A patent/NZ581303A/en not_active IP Right Cessation
- 2008-06-03 SI SI200831067T patent/SI2152748T1/sl unknown
- 2008-06-03 PL PL08768087T patent/PL2152748T3/pl unknown
- 2008-06-03 KR KR1020097025300A patent/KR20100021581A/ko not_active Application Discontinuation
- 2008-06-03 ES ES08768087T patent/ES2432798T3/es active Active
- 2008-06-03 US US12/156,590 patent/US8846871B2/en not_active Expired - Fee Related
- 2008-06-03 CA CA2687866A patent/CA2687866C/en not_active Expired - Fee Related
- 2008-06-03 BR BRPI0811382-3A2A patent/BRPI0811382A2/pt active Search and Examination
- 2008-06-03 MX MX2009013199A patent/MX2009013199A/es active IP Right Grant
- 2008-06-04 CL CL2008001634A patent/CL2008001634A1/es unknown
- 2008-06-04 AR ARP080102361A patent/AR066846A1/es unknown
- 2008-06-04 TW TW097120767A patent/TWI458737B/zh not_active IP Right Cessation
-
2009
- 2009-11-17 IL IL202183A patent/IL202183A0/en unknown
- 2009-12-02 CR CR11139A patent/CR11139A/es unknown
- 2009-12-04 EC EC2009009785A patent/ECSP099785A/es unknown
- 2009-12-23 CO CO09147474A patent/CO6150200A2/es unknown
-
2010
- 2010-01-04 MA MA32476A patent/MA31502B1/fr unknown
- 2010-08-09 HK HK10107588.1A patent/HK1141040A1/xx not_active IP Right Cessation
-
2013
- 2013-09-30 JP JP2013205246A patent/JP2014033675A/ja not_active Withdrawn
- 2013-11-12 CY CY20131101002T patent/CY1114690T1/el unknown
- 2013-11-20 HR HRP20131107AT patent/HRP20131107T1/hr unknown
-
2014
- 2014-02-11 US US14/177,452 patent/US9533042B2/en not_active Expired - Fee Related
- 2014-02-11 US US14/177,435 patent/US20140296488A1/en not_active Abandoned
-
2015
- 2015-02-04 IL IL237083A patent/IL237083A0/en unknown
- 2015-02-04 IL IL237082A patent/IL237082A0/en unknown
- 2015-02-20 CR CR20150088A patent/CR20150088A/es unknown
- 2015-03-13 PH PH12015500550A patent/PH12015500550A1/en unknown
-
2016
- 2016-03-04 JP JP2016042395A patent/JP6426640B2/ja not_active Expired - Fee Related
- 2016-11-22 US US15/359,098 patent/US20170233486A1/en not_active Abandoned
-
2017
- 2017-10-02 US US15/722,635 patent/US10005844B2/en not_active Expired - Fee Related
- 2017-12-27 JP JP2017251778A patent/JP2018082713A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2008001634A1 (es) | Anticuerpo de la region regulatoria negativa anti-notch1 aislado; polinucleotido que lo codifica; vector y celula huesped; metodo de produccion; composicion que lo comprende; y su uso para preparar un medicamento para tratar un trastorno asociado con un aumento en la señalizacion o expresion de notch1 en un individuo. | |
BR112019011450A2 (pt) | células naturais killer modificadas e uso das mesmas | |
MX2020004578A (es) | Composiciones de casz y metodos de uso. | |
AR082017A1 (es) | Anticuerpos anti-axl (receptor de tirosina quinasas) y metodos de uso | |
PE20140673A1 (es) | Nuevos moduladores y metodos para su uso | |
ES2675375T3 (es) | Anticuerpos monoclonales contra claudina 18 para el tratamiento del cáncer | |
RS53009B (en) | IDENTIFICATION OF TUMOR RELATED ANTIGENS FOR THE TREATMENT OF TREATMENT | |
AR068767A1 (es) | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina | |
TR201900649T4 (tr) | Oküler hastalıkların tedavisi için mrna tedavisi. | |
AR085281A1 (es) | Moduladores de la proteina tirosina quinasa 7 (ptk7) y metodos para su uso | |
MX2019011656A (es) | Formatos mejorados de receptor de union a antigeno. | |
AR073425A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina | |
PE20141166A1 (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
PE20140190A1 (es) | Moduladores de proteinas notum y metodos de uso | |
MX360208B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
MX360211B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
CL2019003404A1 (es) | Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico.(divisional solicitud 201702407) | |
BRPI0808940A8 (pt) | anticorpo humano ou fragmento de ligação do mesmo, antígeno, polinucleotídeo, vetor, célula hospedeira, método para preparar um anticorpo ou um fragmento de ligação ou cadeia(s) de imunoglobulina do mesmo, anticorpo, cadeia de imunoglobulina ou um fragmento de ligação do mesmo, composição, usos do anticorpo ou fragmento de ligação, de um antígeno, de um polinucleotídeo, de um vetor, ou de uma célula, e de uma molécula de ligação a antígeno tumoral, método para clonagem molecular de um anticorpo, e, kit para o diagnóstico de um tumor | |
AR099068A1 (es) | Anticuerpo anti-netrina-1 | |
PE20191786A1 (es) | Anticuerpo monoclonal para pd-l1 | |
MX2021008131A (es) | Metodos y composiciones para el tratamiento de la enfermedad de fabry. | |
PE20160528A1 (es) | Anticuerpos | |
AR085167A1 (es) | Polipeptidos de porphyromonas gingivalis, metodo de tratamiento, uso, anticuerpo y kit | |
PE20210918A1 (es) | Composiciones y metodos para el tratamiento de la distrofia macular | |
MX2009003636A (es) | Nuevos peptidos para tratar y prevenir trastornos relacionados al sistema inmunitario, incluyendo el tratamiento y prevencion de la infeccion por modulacion de la inmunidad innata. |